These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 30588904)

  • 81. Pimavanserin: An Inverse Agonist Antipsychotic Drug.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2016 Jun; 54(6):21-4. PubMed ID: 27245248
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis.
    Tampi RR; Tampi DJ; Young JJ; Balachandran S; Hoq RA; Manikkara G
    World J Psychiatry; 2019 Jun; 9(3):47-54. PubMed ID: 31211112
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Treatment of Psychosis in Parkinson's disease and sudden death.
    Kyle K; Bronstein JM
    Parkinsonism Relat Disord; 2020 Oct; 79():127. PubMed ID: 32943345
    [No Abstract]   [Full Text] [Related]  

  • 84. Pimavanserin (Nuplazid) for Parkinson's disease psychosis.
    Med Lett Drugs Ther; 2016 Jun; 58(1496):74-5. PubMed ID: 27249096
    [No Abstract]   [Full Text] [Related]  

  • 85. Dementia-related psychosis and the potential role for pimavanserin.
    Cummings JL; Devanand DP; Stahl SM
    CNS Spectr; 2022 Feb; 27(1):7-15. PubMed ID: 32811586
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study.
    Layton JB; Forns J; Turner ME; Dempsey C; Bartsch JL; Anthony MS; Danysh HE; Ritchey ME; Demos G
    Drugs Real World Outcomes; 2022 Mar; 9(1):9-22. PubMed ID: 34718963
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Treatment of psychosis in Parkinson's disease: safety considerations.
    Fernandez HH; Trieschmann ME; Friedman JH
    Drug Saf; 2003; 26(9):643-59. PubMed ID: 12814332
    [TBL] [Abstract][Full Text] [Related]  

  • 88. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
    Caraci F; Santagati M; Caruso G; Cannavò D; Leggio GM; Salomone S; Drago F
    F1000Res; 2020; 9():. PubMed ID: 32695312
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis.
    Longardner K; Wright BA; Alakkas A; You H; Xu R; Liu L; Nahab FB
    PLoS One; 2023; 18(1):e0278262. PubMed ID: 36706079
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Evaluating pimavanserin tartrate as a treatment in Parkinson's disease.
    Müller T
    Expert Opin Pharmacother; 2024 Oct; ():. PubMed ID: 39403823
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Pimavanserin in the Treatment of Parkinson's Disease Psychosis: Meta-analysis and Meta-regression of Randomized Clinical Trials.
    Mansuri Z; Reddy A; Vadukapuram R; Trivedi C; Amara A
    Innov Clin Neurosci; 2022; 19(1-3):46-51. PubMed ID: 35382074
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Can pimavanserin help patients with Parkinson disease psychosis?
    de la Cruz J; Canal C
    JAAPA; 2019 Jan; 32(1):44-45. PubMed ID: 30589736
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Update on the treatment of Parkinson's disease psychosis: role of pimavanserin.
    Combs BL; Cox AG
    Neuropsychiatr Dis Treat; 2017; 13():737-744. PubMed ID: 28331324
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Parkinson's disease psychosis 2010: a review article.
    Friedman JH
    Parkinsonism Relat Disord; 2010 Nov; 16(9):553-60. PubMed ID: 20538500
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine.
    Moreno GM; Gandhi R; Lessig SL; Wright B; Litvan I; Nahab FB
    Neurology; 2018 Oct; 91(17):797-799. PubMed ID: 30258020
    [No Abstract]   [Full Text] [Related]  

  • 96. Quetiapine, Clozapine, and Pimavanserin Treatment Response in Monogenic Parkinson's Disease Psychosis: A Systematic Review.
    Colijn MA
    J Neuropsychiatry Clin Neurosci; 2024 Jul; ():0. PubMed ID: 39034670
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Combined Pimavanserin and Maintenance Electroconvulsive Therapy: A Novel Approach to Parkinson's Disease Psychosis.
    Imlay RK; Alsayed M; Starcher M; Tager A; Griffith J
    Cureus; 2024 Jul; 16(7):e64316. PubMed ID: 39130906
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Psychosis in Parkinson's disease: therapeutic options.
    Hasnain M
    Drugs Today (Barc); 2011 May; 47(5):353-67. PubMed ID: 22013566
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.
    Stahl SM
    CNS Spectr; 2016 Aug; 21(4):271-5. PubMed ID: 27503570
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators.
    Yasue I; Matsunaga S; Kishi T; Fujita K; Iwata N
    J Alzheimers Dis; 2016; 50(3):733-40. PubMed ID: 26757194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.